Michael Lytton has left his post as general partner at Boston venture firm Oxford Bioscience Partners to be executive vice president of business development at Cambridge, MA-based biotech powerhouse Biogen Idec (NASDAQ:[[ticker:BIIB]]), according to a press release. Lytton, a well-known venture capitalist who joined Oxford in 2001, will now be on the opposite side of deal talks from where he has sat as a board member with public and private life sciences startups in Oxford’s portfolio. A Biogen spokeswoman said that Lytton started work for the company today.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
